ALK and non-small cell lung carcinoma: The prevalence of ALK fusion events in NSCLC is 4–7%, for ROS1 prevalence is 1–3%, and for RET it is 1–2% [6–8], while MET exon 14 skipping has a prevalence of 3% [8].